XML 31 R24.htm IDEA: XBRL DOCUMENT v3.25.2
Collaboration Agreements, License Agreement and Revenues (Tables)
 6 Months Ended
Jun. 30, 2025
Schedule of Drug Product Revenue

Drug product revenue from commercial-grade active pharmaceutical ingredient (“API”) or bulk drug product sales to Astellas and AstraZeneca was as follows for the three and six months ended June 30, 2025 and 2024 (in thousands):

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Astellas Japan Agreement

 

$

44

 

 

$

(366

)

 

$

1,825

 

 

$

(2,571

)

Astellas Europe Agreement

 

 

1,171

 

 

 

1,095

 

 

 

1,986

 

 

 

2,116

 

AstraZeneca U.S./RoW Agreement

 

 

—

 

 

 

—

 

 

 

—

 

 

 

25,671

 

Drug product revenue, net

 

$

1,215

 

 

$

729

 

 

$

3,811

 

 

$

25,216

 
Drug Product Revenue, Net [Member]  
Roll-forward of Related Contract Liabilities

The following table includes a roll-forward of the above-mentioned deferred revenues that are considered as contract liabilities related to drug product (in thousands):

 

 

 

Balance at
December 31, 2024

 

 

Recognized as Revenue

 

 

Reclassified to Accrued Liability / Accounts Payable

 

 

Balance at
June 30, 2025

 

Drug product revenue - deferred revenue:

 

 

 

 

 

 

 

 

 

 

 

 

Astellas Europe Agreement

 

$

(9,901

)

 

$

1,986

 

 

$

1,327

 

 

$

(6,588

)
AstraZeneca Agreements [Member]  
Roll-forward of Related Contract Liabilities

The following table includes a roll-forward of the related deferred revenue that is considered as a contract liability (in thousands):

 

 

 

Balance at
December 31, 2024

 

 

Additions

 

 

Recognized
as Revenue
(Discontinued
Operations)

 

 

Currency
Translation
and Other

 

 

Balance at
June 30, 2025

 

AstraZeneca China performance obligation
   - deferred revenue

 

$

(132,097

)

 

$

(63,509

)

 

$

53,308

 

 

$

(649

)

 

$

(142,947

)